The University of Southampton
University of Southampton Institutional Repository

A prospective, multicenter, clinical study to evaluate the safety, pharmacokinetics, and efficacy of bleed outcomes, with HemoRel-A® in severe hemophilia A patients

A prospective, multicenter, clinical study to evaluate the safety, pharmacokinetics, and efficacy of bleed outcomes, with HemoRel-A® in severe hemophilia A patients
A prospective, multicenter, clinical study to evaluate the safety, pharmacokinetics, and efficacy of bleed outcomes, with HemoRel-A® in severe hemophilia A patients

Purpose: To evaluate efficacy for an on-demand treatment of acute bleeding events, pharmacokinetics, safety, and tolerability of HemoRel-A® in severe hemophilia A. Methods: A total of 44 male subjects with severe hemophilia A with an annualized bleed rate of 12 while on-demand treatment with factor VIII (FVIII) were enrolled in the study and received HemoRel-A® for bleed treatment. The efficacy of HemoRel-A® was evaluated based on a four-point scale (excellent, good, moderate, or none). Six-point pharmacokinetic (PK) assessment was performed following a single dose of 50 IU/kg in 12 subjects after a 7-day wash-out period. Safety evaluations were performed at each visit and inhibitor testing was performed in all patients at screening and end of study. Results: Forty-four male subjects received at least a single dose of the study medication and were included in the intent-to-treat (ITT) analysis and safety outcome. In 23 (7.52%) out of the 306 bleeding events, HemoRel-A® efficacy was rated as excellent, in 272 (88.89 %) bleeds it was rated as good, and in 11 (3.68%) bleeding events it was rated as moderate. No failure of efficacy was noted in any of the bleeding events. Thus overall out of 306 bleeding events, 295 (96.41%) showed excellent or good efficacy. Pharmacokinetic assessment based on plasma FVIII activity measured by the chromogenic assay in 12 patients showed comparative results similar to FVIII preparations. A total of 12 adverse events (AEs) were reported in this study. There was no inhibitor development in this previously treated patients (PTP) cohort. Conclusion: HemoRel-A® was established to be efficacious and safe in the treatment of acute bleeding events in subjects with severe hemophilia A.

0004-5772
72-75
Mewada, Mayur
68857578-9cd6-408e-81e5-c2e6fc0bdd31
Sanyal, Subhaprakash
25aa84a8-fdff-4d54-b4ba-b92ab2800a2a
Rangarajan, Savita
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Apsangikar, Prasad
c25e2bd0-650d-45aa-8088-bd8f1bcdcb9b
Yadav, Ajay Kumar
6eac9c5e-23a0-4fac-be03-7b3662c5d681
Naik, Manoj
d1294e61-b246-4bbd-a630-a4193d445c77
Nair, Santosh
493bfce1-caab-4529-bd7b-5dca5a41e82a
Mewada, Mayur
68857578-9cd6-408e-81e5-c2e6fc0bdd31
Sanyal, Subhaprakash
25aa84a8-fdff-4d54-b4ba-b92ab2800a2a
Rangarajan, Savita
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Apsangikar, Prasad
c25e2bd0-650d-45aa-8088-bd8f1bcdcb9b
Yadav, Ajay Kumar
6eac9c5e-23a0-4fac-be03-7b3662c5d681
Naik, Manoj
d1294e61-b246-4bbd-a630-a4193d445c77
Nair, Santosh
493bfce1-caab-4529-bd7b-5dca5a41e82a

Mewada, Mayur, Sanyal, Subhaprakash, Rangarajan, Savita, Apsangikar, Prasad, Yadav, Ajay Kumar, Naik, Manoj and Nair, Santosh (2022) A prospective, multicenter, clinical study to evaluate the safety, pharmacokinetics, and efficacy of bleed outcomes, with HemoRel-A® in severe hemophilia A patients. The Journal of the Association of Physicians of India, 70 (7), 72-75, [ISSN 0004-5772]. (doi:10.5005/japi-11001-0039).

Record type: Article

Abstract

Purpose: To evaluate efficacy for an on-demand treatment of acute bleeding events, pharmacokinetics, safety, and tolerability of HemoRel-A® in severe hemophilia A. Methods: A total of 44 male subjects with severe hemophilia A with an annualized bleed rate of 12 while on-demand treatment with factor VIII (FVIII) were enrolled in the study and received HemoRel-A® for bleed treatment. The efficacy of HemoRel-A® was evaluated based on a four-point scale (excellent, good, moderate, or none). Six-point pharmacokinetic (PK) assessment was performed following a single dose of 50 IU/kg in 12 subjects after a 7-day wash-out period. Safety evaluations were performed at each visit and inhibitor testing was performed in all patients at screening and end of study. Results: Forty-four male subjects received at least a single dose of the study medication and were included in the intent-to-treat (ITT) analysis and safety outcome. In 23 (7.52%) out of the 306 bleeding events, HemoRel-A® efficacy was rated as excellent, in 272 (88.89 %) bleeds it was rated as good, and in 11 (3.68%) bleeding events it was rated as moderate. No failure of efficacy was noted in any of the bleeding events. Thus overall out of 306 bleeding events, 295 (96.41%) showed excellent or good efficacy. Pharmacokinetic assessment based on plasma FVIII activity measured by the chromogenic assay in 12 patients showed comparative results similar to FVIII preparations. A total of 12 adverse events (AEs) were reported in this study. There was no inhibitor development in this previously treated patients (PTP) cohort. Conclusion: HemoRel-A® was established to be efficacious and safe in the treatment of acute bleeding events in subjects with severe hemophilia A.

Text
JAPI0039_p72_75 - Version of Record
Download (186kB)

More information

Accepted/In Press date: 13 April 2022
Published date: 1 July 2022
Additional Information: Publisher Copyright: © The Author(s).

Identifiers

Local EPrints ID: 470307
URI: http://eprints.soton.ac.uk/id/eprint/470307
ISSN: 0004-5772
PURE UUID: 2fc66ed5-c6ff-4195-ae61-ca1531d94dc5
ORCID for Savita Rangarajan: ORCID iD orcid.org/0000-0001-7367-133X

Catalogue record

Date deposited: 06 Oct 2022 16:30
Last modified: 06 Jun 2024 02:08

Export record

Altmetrics

Contributors

Author: Mayur Mewada
Author: Subhaprakash Sanyal
Author: Prasad Apsangikar
Author: Ajay Kumar Yadav
Author: Manoj Naik
Author: Santosh Nair

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×